4/1
07:05 am
clsd
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Low
Report
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
3/31
08:16 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/29
09:02 am
clsd
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations [Yahoo! Finance]
Medium
Report
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations [Yahoo! Finance]
3/28
08:50 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
Medium
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $6.00 price target on the stock.
3/28
08:20 am
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its price target lowered by analysts at Needham & Company LLC from $6.00 to $4.00. They now have a "buy" rating on the stock.
3/27
04:12 pm
clsd
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/27
04:05 pm
clsd
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/24
07:05 am
clsd
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Medium
Report
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
3/20
07:33 am
clsd
Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit [Yahoo! Finance]
Neutral
Report
Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit [Yahoo! Finance]
3/20
07:05 am
clsd
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
High
Report
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
3/18
11:03 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/12
07:38 am
clsd
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 [Yahoo! Finance]
Low
Report
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 [Yahoo! Finance]
3/12
07:05 am
clsd
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
Low
Report
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
3/6
02:24 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
3/6
02:24 pm
clsd
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Clearside Biomedical, Inc. (NASDAQ: CLSD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/6
07:43 am
clsd
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD [Yahoo! Finance]
Medium
Report
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD [Yahoo! Finance]
3/6
07:05 am
clsd
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
High
Report
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
2/20
07:05 am
clsd
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Low
Report
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
2/10
07:05 am
clsd
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
Medium
Report
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
2/5
07:00 am
clsd
MedPharm appoints Bill Humphries as new CEO [Yahoo! Finance]
High
Report
MedPharm appoints Bill Humphries as new CEO [Yahoo! Finance]
2/4
07:05 am
clsd
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Low
Report
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
1/28
07:05 am
clsd
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Low
Report
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
1/22
08:31 am
clsd
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore [Yahoo! Finance]
Low
Report
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore [Yahoo! Finance]
1/22
07:05 am
clsd
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Low
Report
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore